Drug Profile
Research programme: cystic fibrosis therapeutics - BioMarin
Alternative Names: BMN 174; BMN 175Latest Information Update: 03 Feb 2010
Price :
$50
*
At a glance
- Originator University of California at San Francisco
- Developer BioMarin Pharmaceutical
- Class Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 22 Aug 2007 Preclinical trials in Cystic fibrosis in USA (unspecified route)